scholarly article | Q13442814 |
P819 | ADS bibcode | 2013PLoSO...855038V |
P356 | DOI | 10.1371/JOURNAL.PONE.0055038 |
P932 | PMC publication ID | 3557242 |
P698 | PubMed publication ID | 23383047 |
P5875 | ResearchGate publication ID | 235402969 |
P50 | author | Samir Abdurahman | Q55173050 |
Staffan Nilsson | Q55457264 | ||
Tatsuo Kanda | Q61112129 | ||
Magnus Gisslén | Q90302675 | ||
Anders Sönnerborg | Q90893354 | ||
Piotr Nowak | Q37841236 | ||
Jessica Nyström | Q42996907 | ||
P2093 | author name string | Lars-Magnus Andersson | |
Jan Vesterbacka | |||
Hiroyuki Funaoka | |||
Babilonia Barqasho | |||
P2860 | cites work | Emerging concepts in the immunopathogenesis of AIDS | Q22241984 |
Microbial translocation is a cause of systemic immune activation in chronic HIV infection | Q22251054 | ||
Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy | Q46481116 | ||
Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy | Q46812278 | ||
A pilot study on the noninvasive evaluation of intestinal damage in celiac disease using I-FABP and L-FABP. | Q48023468 | ||
Immune reconstitution in HIV+ subjects on lopinavir/ritonavir-based HAART according to the severity of pre-therapy CD4+. | Q48658905 | ||
Diagnosis of ischemic small bowel disease by measurement of serum intestinal fatty acid-binding protein in patients with acute abdomen: a multicenter, observer-blinded validation study. | Q51058766 | ||
Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation. | Q54415328 | ||
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count | Q56334717 | ||
Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility | Q79175503 | ||
Intestinal fatty acid binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitis | Q80507477 | ||
Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis | Q82223323 | ||
Development of a high-specificity sandwich ELISA system for the quantification of human intestinal fatty acid-binding protein (I-FABP) concentrations | Q83122025 | ||
Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events | Q32025738 | ||
Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome | Q33547430 | ||
Reappearance of founder virus sequence in human immunodeficiency virus type 1-infected patients | Q33816212 | ||
Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy | Q33873507 | ||
Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV neuroAIDS | Q33873798 | ||
Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy | Q33924628 | ||
Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda | Q34359439 | ||
Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy | Q34384134 | ||
Plasma levels of soluble CD14 independently predict mortality in HIV infection | Q34764002 | ||
Impact of HMGB1/TLR Ligand Complexes on HIV-1 Replication: Possible Role for Flagellin during HIV-1 Infection | Q36032021 | ||
In vitro and in vivo effects of HIV protease inhibitors on apoptosis | Q36068283 | ||
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy | Q36499290 | ||
HIV protease inhibitors impact on apoptosis. | Q37066766 | ||
Flagellin as an adjuvant: cellular mechanisms and potential. | Q37130379 | ||
Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. | Q37207653 | ||
Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors | Q37290836 | ||
Cardiovascular disease and HIV infection: host, virus, or drugs? | Q37521745 | ||
Bacterial flagellin is a dominant antigen in Crohn disease. | Q37698878 | ||
Role of CD14 in lung inflammation and infection | Q37710762 | ||
Long-term impacts of antibiotic exposure on the human intestinal microbiota | Q37779673 | ||
Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection | Q37862747 | ||
Twenty years of HIV-1 non-nucleoside reverse transcriptase inhibitors: time to reevaluate their toxicity | Q37869166 | ||
Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy | Q38440519 | ||
Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor | Q39652630 | ||
Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study | Q42551648 | ||
Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. | Q42970792 | ||
Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients | Q43067974 | ||
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients | Q43228365 | ||
The role of CD14 gene promoter polymorphism in tuberculosis susceptibility | Q44183724 | ||
HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens | Q44660024 | ||
Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy | Q44871108 | ||
Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation | Q46157814 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | lopinavir | Q422585 |
efavirenz | Q422645 | ||
anti-retroviral agent | Q50430310 | ||
P304 | page(s) | e55038 | |
P577 | publication date | 2013-01-28 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy | |
P478 | volume | 8 |
Q38856670 | Brief Report: Differential Associations of Interleukin 6 and Intestinal Fatty Acid-Binding Protein With Progressive Untreated HIV-1 Infection in Rakai, Uganda. |
Q35945416 | Complexities of Gut Microbiome Dysbiosis in the Context of HIV Infection and Antiretroviral Therapy |
Q33599291 | Contribution of intestinal barrier damage, microbial translocation and HIV-1 infection status to an inflammaging signature |
Q92827882 | Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation |
Q35283132 | Immune activation is associated with increased gut microbial translocation in treatment-naive, HIV-infected children in a resource-limited setting |
Q36957752 | Inflammation, immune activation, and cardiovascular disease in HIV. |
Q93147271 | Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial |
Q35191924 | Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients. |
Q57111128 | Lower pretreatment gut integrity is independently associated with fat gain on antiretroviral therapy |
Q36558287 | Microbial translocation in the pathogenesis of HIV infection and AIDS. |
Q37516139 | Pattern of microbial translocation in patients living with HIV-1 from Vietnam, Ethiopia and Sweden |
Q33727042 | Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection |
Q64902148 | Reduced Transplacental Transfer of Antimalarial Antibodies in Kenyan HIV-Exposed Uninfected Infants. |
Q40121502 | Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers |
Q36957941 | Sex differences in soluble markers vary before and after the initiation of antiretroviral therapy in chronically HIV-infected individuals |
Q33934080 | Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial |
Q46945781 | Very Early ART and Persistent Inflammation in Treated HIV. |
Search more.